

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau

(43) International Publication Date  
20 October 2022 (20.10.2022)



(10) International Publication Number  
**WO 2022/221526 A1**

(51) International Patent Classification:

C07D 231/14 (2006.01) C07D 401/12 (2006.01)  
C07D 401/04 (2006.01)

(21) International Application Number:

PCT/US2022/024805

(22) International Filing Date:

14 April 2022 (14.04.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/174,860 14 April 2021 (14.04.2021) US

(71) Applicant: **BIOCRYST PHARMACEUTICALS, INC.**  
[US/US]; 4505 Emperor Blvd., Suite 200, Durham, NC  
27703 (US).

(72) Inventors: **KOTIAN, Pravin, L.**; 1139 Magnolia Run,  
Birmingham, AL 35226 (US). **BABU, Yarlagadda, S.**;  
4836 Southlake Parkway, Birmingham, AL 35244 (US).  
**ZHANG, Weihe**; 2645 Manchester Court, Vestavia Hills,  
AL 35226 (US). **LU, Peng-Cheng**; 1816 Altadena Ridge  
Place, Vestavia Hills, AL 35243 (US). **DANG, Zhao**; 1226  
Parliament Lane, Vestavia Hills, AL 35216 (US). **RAMAN,**




**Krishnan**; 3739 Spearman Drive, Birmingham, AL 35216  
(US).

(74) Agent: **GORDON, Dana, M.** et al.; Foley Hoag LLP, 155  
Seaport Boulevard, Boston, MA 02210-2600 (US).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,  
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,  
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,  
HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH,  
KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,  
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,  
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,  
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,  
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,  
ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,  
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,  
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,  
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,  
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5



(57) Abstract: Disclosed are compounds of formulae (I) - (IV),  
and pharmaceutically acceptable salts thereof, which are inhibitors of  
kallikrein-related peptidase 5 (KLK5). Also provided are pharmaceutica  
l compositions comprising such a compound, and methods of using the  
compounds and compositions in the treatment or prevention of a disease  
or condition characterized by aberrant KLK5 activity activity, such as  
Netherton Syndrome.

WO 2022/221526 A1

[Continued on next page]

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,  
KM, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

- *of inventorship (Rule 4.17(iv))*

**Published:**

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*